Full history for every metric is available with a Kvantra account
ETHZilla Corporation Common Stock (ATNF)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $bn | -0 | |||||
| Net profit | $bn | -0 | -0 | -0 | -0 | -0 | -451 |
| EPS reported | $ | -5,518 | |||||
| Operating cashflow per share | $ | -0.31 | |||||
| Capex per share | $ | 0.00 | |||||
| FCF per share | $ | -0.31 | |||||
| Free cash flow | $bn | -0 | |||||
| Net debt | $bn | 0 | |||||
| Book value equity | $bn | 0 | |||||
| Book value per share | $ | 2.93 | |||||
| Number of shares | m | 81.65 | |||||
| DPS (TTM paid) | $ | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 2.40 | |||||
| P/S LTM | x | 87.80 | |||||
| P/FCF LTM | x | -22.73 | |||||
| EV/EBITDA LTM | x | -0.00 | |||||
| EV/Sales LTM | x | 124.91 | |||||
| Earnings Yield LTM | % | -78376.6% | |||||
| FCF Yield | % | -4.40% | |||||
| Quality | |||||||
| ROE | % | -188173.4% | |||||
| ROIC | % | -42.20% | |||||
| Operating margin | % | -3565.8% | |||||
| Gross margin | % | 0.00% | |||||
| FCF/Sales | % | -386.33% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | - | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | - | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -0.10 | |||||
| Net Debt/EBITDA | x | -0.00 | |||||
| EBIT/Net interest | x | 0.08 | |||||
| Net debt/market cap | % | 42.27% | |||||
| Net debt/Equity | x | 1.01 | |||||
| Gross debt/equity | x | 1.05 | |||||
Company overview
1180 Life Sciences Corp. is a biotechnology firm currently in the clinical trial phase, dedicated to creating treatments for pressing medical challenges including chronic pain, inflammation, fibrosis, and other related inflammatory conditions. The company's therapeutic pipeline is supported by three primary development platforms: An anti-tumor necrosis factor (anti-TNF) and fibrosis platform is progressing through Phase IIb clinical trials, specifically targeting fibrosis and anti-TNF pathways. A Synthetic Cannabidiol (CBD) Analogs platform, featuring laboratory-created derivatives of CBD, is currently in preclinical development. An a7nAChR platform, which functions as an immune suppressive agent by focusing on the alpha 7 nicotinic acetylcholine receptor, is also undergoing preclinical evaluation. Established in 2016, 1180 Life Sciences Corp. is based in Palo Alto, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ETHZilla Corporation Common Stock (ATNF)
1180 Life Sciences Corp. is a biotechnology firm currently in the clinical trial phase, dedicated to creating treatments for pressing medical challenges including chronic pain, inflammation, fibrosis, and other related inflammatory conditions. The company's therapeutic pipeline is supported by three primary development platforms: An anti-tumor necrosis factor (anti-TNF) and fibrosis platform is progressing through Phase IIb clinical trials, specifically targeting fibrosis and anti-TNF pathways. A Synthetic Cannabidiol (CBD) Analogs platform, featuring laboratory-created derivatives of CBD, is currently in preclinical development. An a7nAChR platform, which functions as an immune suppressive agent by focusing on the alpha 7 nicotinic acetylcholine receptor, is also undergoing preclinical evaluation. Established in 2016, 1180 Life Sciences Corp. is based in Palo Alto, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free